{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:10:50Z","timestamp":1777349450640,"version":"3.51.4"},"reference-count":22,"publisher":"Codon Publications","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergologia et Immunopathologia"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.aller.2019.12.006","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T17:48:03Z","timestamp":1588009683000},"page":"686-693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Activated PI3K-delta syndrome in an Egyptian pediatric cohort with primary immune deficiency"],"prefix":"10.15586","volume":"48","author":[{"given":"Alshymaa A.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alia A.","family":"El Shahaway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameh A.","family":"Hussien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6228","reference":[{"issue":"3","key":"10.1016\/j.aller.2019.12.006_bib0005","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10875-008-9260-x","article-title":"Primary immunodeficiency diseases in Egyptian children: a single-center study","volume":"29","author":"Reda","year":"2009","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.aller.2019.12.006_bib0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10875-017-0465-8","article-title":"The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies","volume":"38","author":"Bousfiha","year":"2018","journal-title":"J Clin Immunol"},{"issue":"4","key":"10.1016\/j.aller.2019.12.006_bib0015","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s10875-014-0003-x","article-title":"ICON: the early diagnosis of congenital immunodeficiencies","volume":"34","author":"Routes","year":"2014","journal-title":"J Clin Immunol"},{"issue":"10","key":"10.1016\/j.aller.2019.12.006_bib0020","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/aps.2015.71","article-title":"PI3K isoform-selective inhibitors: next-generation targeted cancer therapies","volume":"36","author":"Wang","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.aller.2019.12.006_bib0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fonc.2013.00040","article-title":"p110delta PI3 kinase pathway: emerging roles in cancer","volume":"3","author":"Tzenaki","year":"2013","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.aller.2019.12.006_bib0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.aller.2019.12.006_bib0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/ni0403-313","article-title":"The role of PI3K in immune cells","volume":"4","author":"Koyasu","year":"2003","journal-title":"Nat Immunol"},{"issue":"6160","key":"10.1016\/j.aller.2019.12.006_bib0040","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.1243292","article-title":"Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage","volume":"342","author":"Angulo","year":"2013","journal-title":"Science"},{"issue":"369","key":"10.1016\/j.aller.2019.12.006_bib0045","article-title":"Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy","volume":"9","author":"Michalovich","year":"2018","journal-title":"Ontiers Immunol"},{"issue":"8","key":"10.1016\/j.aller.2019.12.006_bib0050","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1073\/pnas.1617244114","article-title":"Conformational disruption of PI3K\u03b4 regulation by immunodeficiency mutations in PIK3CD and PIK3R1","volume":"114","author":"Dornan","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.aller.2019.12.006_bib0055","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1749-6632.2011.06206.x","article-title":"Ten warning signs of primary immunodeficiency: a new paradigm is needed for the 21st century","volume":"1238","author":"Arkwright","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.aller.2019.12.006_bib0060","series-title":"Oxford handbook of medical statistics. Research design, choosing a sample size","first-page":"56","author":"Peacock","year":"2011"},{"issue":"2","key":"10.1016\/j.aller.2019.12.006_bib0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/cei.12706","article-title":"Activating PI3Kdelta mutations in a cohort of 669 patients with primary immunodeficiency","volume":"183","author":"Elgizouli","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.aller.2019.12.006_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21608\/zumj.2014.4360","article-title":"Assessment of primary immunodeficiency disorders among children at Zagazig University Hospital","volume":"20","author":"Hussien","year":"2014","journal-title":"Zagazig Univ Med J"},{"issue":"3","key":"10.1016\/j.aller.2019.12.006_bib0075","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s10875-014-0012-9","article-title":"Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility","volume":"34","author":"Crank","year":"2014","journal-title":"J Clin Immunol"},{"issue":"2","key":"10.1016\/j.aller.2019.12.006_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: A large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.aller.2019.12.006_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.02.020","article-title":"Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase \u03b4 syndrome","volume":"134","author":"Kracker","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.aller.2019.12.006_bib0090","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.4049\/jimmunol.1101602","article-title":"Enhanced Phosphoinositide 3-Kinase \u03b4 activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death","volume":"187","author":"Su\u00e1rez-Fueyo","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.aller.2019.12.006_bib0095","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat Rev Drug Discovery"},{"issue":"5","key":"10.1016\/j.aller.2019.12.006_bib0100","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ajpath.2012.01.030","article-title":"PI3 kinase \u03b4 is a key regulator of synoviocyte function in rheumatoid arthritis","volume":"180","author":"Bartok","year":"2012","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.aller.2019.12.006_bib0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nyas.12039","article-title":"Targeting phosphoinositide 3\u2010kinase \u03b4 for the treatment of respiratory diseases","volume":"1280","author":"Sriskantharajah","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.aller.2019.12.006_bib0110","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pupt.2017.08.008","article-title":"Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3K\u03b4 inhibitor under development for the treatment of COPD","volume":"46","author":"Cahn","year":"2017","journal-title":"Pulm Pharmacol Ther"}],"container-title":["Allergologia et Immunopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301054620300306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301054620300306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T10:48:27Z","timestamp":1666435707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301054620300306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0301054620300306"],"URL":"https:\/\/doi.org\/10.1016\/j.aller.2019.12.006","relation":{},"ISSN":["0301-0546"],"issn-type":[{"value":"0301-0546","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activated PI3K-delta syndrome in an Egyptian pediatric cohort with primary immune deficiency","name":"articletitle","label":"Article Title"},{"value":"Allergologia et Immunopathologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aller.2019.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 SEICAP. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}